Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555256 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00555256: Completed Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Washington University School of Medicine.
NCT00555256 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Washington University School of Medicine. The registered enrollment target is 19 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555256, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To define the optimal dose of sunitinib when given in combination with rapamycin 2mg. To determine the maximum tolerated dosage of sunitinib and rapamycin given in this fashion. To determine the how many times and how severe other toxicities of this combination therapy. To determine how quickly the patient(s) will respond the the drug, overall survival and time to progression for this combination therapy.
Conditions Studied
Interventions
- DRUG sunitinib and rapamycin (Drug will be held)
Study Locations (1)
Missouri
- Washington University School of medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT00555256 record still lists
NCT00555256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which sunitinib and rapamycin (Drug will be held) is the first listed.
NCT00555256 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00555256 about?
NCT00555256 is a clinical study titled "A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)". To define the optimal dose of sunitinib when given in combination with rapamycin 2mg. To determine the maximum tolerated dosage of sunitinib and rapamycin given in this fashion. To determine the how many times and how severe other toxicities of this combination therapy. To determine how quickly t...
What is the current status of trial NCT00555256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2007-11. Estimated completion is 2012-12.
What conditions does trial NCT00555256 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00555256?
The interventions under investigation include: sunitinib and rapamycin (Drug will be held) (DRUG).
Who is sponsoring clinical trial NCT00555256?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00555256 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00555256's enrollment target sits among peer trials
19 422nd of 454 higher than 32 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia